Recordati Rare Diseases Announces Real-World Data on Long-Term Safety of ENJAYMO® (sutimlimab-jome) in Cold Agglutinin Disease and Cold Agglutinin Syndrome (CAD/CAS) at American Society of Hematology (ASH) Annual Meeting

Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment duration of more than two years ENJAYMO® is approved for treatment of hemolysis...

Read More